BURNS, published by Elsevier Science Ltd, is a leading academic journal focused on the multidisciplinary study of burn injuries and their management. With a strong reputation in the field, it holds impressive rankings, including Q1 in Emergency Medicine and Q2 in Critical Care and Intensive Care Medicine, reflecting its significant impact on clinical practices and research advancements. The journal, with an ISSN of 0305-4179 and E-ISSN 1879-1409, has served the academic community since 1974 and continues to provide a platform for innovative research until 2024 and beyond. While it is not currently an open-access publication, BURNS remains an essential resource for researchers, practitioners, and students seeking to enhance their understanding of burn care and associated medical fields. With a focus on critical insights, the journal plays a vital role in advancing knowledge and improving patient outcomes in burn treatment and rehabilitation.

Journal of Acute Disease is a leading peer-reviewed publication dedicated to the timely dissemination of research focused on acute medical conditions, enhancing our understanding and management of these vital health issues. Published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, this Open Access journal has been committed to providing unrestricted access to high-quality research since its establishment in 2012, ensuring that professionals, researchers, and students can readily benefit from groundbreaking studies and innovative practices in the field. With a focus on enhancing clinical practice through rigorous research, the journal covers a wide range of topics including epidemiology, diagnostics, treatment protocols, and patient outcomes related to acute diseases. With its robust editorial team and a global readership, the Journal of Acute Disease serves as an essential platform for advancing knowledge and improving healthcare delivery worldwide.

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.

INFECTION is a prestigious journal, published by Springer Heidelberg, that serves as a leading platform for the dissemination of critical research in the fields of Infectious Diseases, Microbiology, and Medicine. With an impressive Q1 ranking in multiple categories such as Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, the journal is recognized for its high-quality content and impactful contributions to the scientific community, as evidenced by its Scopus rankings placing it in the top 10th percentiles. Since its inception in 1973, and projected to continue until 2024, INFECTION has established itself as a vital resource for researchers, healthcare professionals, and students keen to explore the latest findings and advancements in infectious diseases. The journal provides a rigorous peer-review process, ensuring that only high-quality studies are published, making it an essential read for those seeking to deepen their understanding and stay abreast of the rapidly evolving landscape in infection research.

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

Therapeutic Advances in Infectious Disease is a distinguished journal published by SAGE Publications Ltd, dedicated to advancing knowledge in the vital field of infectious diseases and pharmacology. With an impactful Open Access model since 2019, the journal facilitates unrestricted access to a wealth of high-quality research, enabling researchers, clinicians, and educators to stay at the forefront of infectious disease management and treatment. As a recognition of its contribution to the scientific community, the journal holds a prestigious Q1 quartile ranking in both Infectious Diseases and Medical Pharmacology as of 2023, underscoring its influence and relevance in these domains. The journal is positioned favorably within the Scopus rankings, with an impressive standing in the diverse categories of Medicine, emphasizing its commitment to disseminating innovative research. Through a rigorous peer-review process and a broad scope that covers therapeutic advancements, Therapeutic Advances in Infectious Disease serves as an essential resource for anyone involved in combating infectious diseases, offering insights that drive clinical applications and enhance patient care.

CARDIOLOGY, published by KARGER, is a renowned scholarly journal dedicated to the advancement of research in the fields of cardiology and cardiovascular medicine. Since its inception in 1937, the journal has consistently provided a platform for high-quality, peer-reviewed articles that contribute to the understanding and treatment of heart and vascular diseases. With an impressive convergence through 2024, CARDIOLOGY holds a respectable Q2 ranking in both the Cardiology and Cardiovascular Medicine and Pharmacology (medical) categories, placing it within the 53rd and 45th percentiles of respective Scopus ranks. Based in Switzerland, the journal serves as an essential resource for researchers and practitioners aiming to stay abreast of cutting-edge developments and evidence-based practices in cardiovascular health. While it currently does not offer open access options, its commitment to rigorous scientific standards solidifies its significance within the academic community. We invite readers to explore the latest research findings and contribute to this vital field through publications in CARDIOLOGY.

BMC Infectious Diseases is a premier open-access journal published by BMC in the United Kingdom, dedicated to the field of infectious diseases. Established in 2001, this journal has been at the forefront of disseminating high-quality, peer-reviewed research, contributing significantly to the global understanding of infectious pathogens and their impact on public health. With a 2023 Scopus ranking of #100 out of 344 in the Medicine - Infectious Diseases category, and a notable Q1 quartile classification, it stands as a vital resource for researchers and professionals alike. Authors benefit from the journal's broad reach and visibility, ensuring their work is accessible to a wide audience. Access options are fully open, allowing for seamless dissemination of knowledge in the ongoing battle against infectious diseases. With an established history of publishing groundbreaking studies, BMC Infectious Diseases plays a crucial role in addressing critical issues and advancing research in the ever-evolving landscape of infectious diseases.

Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.

Infectious Diseases, published by TAYLOR & FRANCIS LTD, is a leading academic journal dedicated to advancing research in the field of infectious diseases and microbiology. With an impressive impact factor and categorized in Q1 in multiple areas including Immunology and Microbiology, this journal serves as a critical platform for researchers, practitioners, and students to disseminate their findings and stay abreast of current advancements. The journal is recognized for its rigorous peer-review process and aims to foster innovation and collaboration across disciplines from 2015 to 2024. It boasts a robust Scopus ranking, positioning it favorably among the top-tier of journals in the relevant fields, making it an essential resource for anyone involved in infectious disease research. Access options are available, ensuring that the latest research is accessible to a global audience, thus emphasizing the journal's commitment to promoting knowledge and understanding in the ever-evolving landscape of infectious diseases.